These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22672003)

  • 1. Response to Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?
    O'Shea JG
    Clin Exp Optom; 2012 Sep; 95(5):541-3. PubMed ID: 22672003
    [No Abstract]   [Full Text] [Related]  

  • 2. Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?
    Aujla JS
    Clin Exp Optom; 2012 Sep; 95(5):538-40. PubMed ID: 22621684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Age-related visual loss].
    Neubauer AS; Kernt M
    MMW Fortschr Med; 2013 Feb; 155(2):36-7. PubMed ID: 23573743
    [No Abstract]   [Full Text] [Related]  

  • 4. Can genetic factors predict response to antivascular endothelial growth factor therapy in age-related macular degeneration?
    Micieli JA
    Can J Ophthalmol; 2011 Dec; 46(6):549-51. PubMed ID: 22153646
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.
    Silver J
    JAMA; 2014 Jul; 312(1):23-4. PubMed ID: 24860863
    [No Abstract]   [Full Text] [Related]  

  • 6. Bevacizumab in ophthalmology: the controversy moves forward.
    Gillies MC
    Clin Exp Ophthalmol; 2010 May; 38(4):333-4. PubMed ID: 20642588
    [No Abstract]   [Full Text] [Related]  

  • 7. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
    Hawkes N
    BMJ; 2012 May; 344():e3275. PubMed ID: 22573655
    [No Abstract]   [Full Text] [Related]  

  • 8. New treatments for age-related macular degeneration.
    Avery RL
    Lancet; 2007 Oct; 370(9597):1479-80; author reply 1480. PubMed ID: 17964341
    [No Abstract]   [Full Text] [Related]  

  • 9. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
    Campbell RJ; Bell CM; Paterson JM; Bronskill SE; Moineddin R; Whitehead M; Gill SS
    Ophthalmology; 2012 Aug; 119(8):1604-8. PubMed ID: 22717458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
    J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab for the treatment of neovascular age-related macular degeneration.
    Pitlick JM; Vecera KF; Barnes KN; Reski JW; Forinash AB
    Ann Pharmacother; 2012 Feb; 46(2):290-6. PubMed ID: 22274144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab.
    Jiang S; Park C; Barner JC
    J Clin Pharm Ther; 2014 Jun; 39(3):234-9. PubMed ID: 24635444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shanghai eye treatment outbreak: bevacizumab therapy for AMD in China.
    Huang HB; Pan Y; Liu T
    Clin Exp Optom; 2013 Jan; 96(1):106-8. PubMed ID: 23051067
    [No Abstract]   [Full Text] [Related]  

  • 14. Why using Avastin for eye disease is so difficult.
    Torjesen I
    BMJ; 2012 May; 344():e3012. PubMed ID: 22549057
    [No Abstract]   [Full Text] [Related]  

  • 15. Bevacizumab: a new hope?
    Madhusudhana KC; Newsom RS
    Eye (Lond); 2009 Sep; 23(9):1755-7. PubMed ID: 19741717
    [No Abstract]   [Full Text] [Related]  

  • 16. Intravitreal avastin: the low cost alternative to lucentis?
    Rosenfeld PJ
    Am J Ophthalmol; 2006 Jul; 142(1):141-3. PubMed ID: 16815262
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparing ranibizumab with bevacizumab.
    Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S
    Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.
    Schmid MK; Bachmann LM; Fäs L; Kessels AG; Job OM; Thiel MA
    Br J Ophthalmol; 2015 Feb; 99(2):141-6. PubMed ID: 25271911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Debate on the various anti-vascular endothelial growth factor drugs.
    Khalili MR; Hosseini H
    Indian J Ophthalmol; 2008; 56(3):255-6; author reply 256. PubMed ID: 18417837
    [No Abstract]   [Full Text] [Related]  

  • 20. [Anti-VEGF: one drug for different conditions?].
    Cohen SY; Massin P; Souied E
    J Fr Ophtalmol; 2013 Jan; 36(1):2-4. PubMed ID: 23290491
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.